Clinical trial · no report yet · Phase 2

NCT04417660 trial: what clinicians have said so far

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

NCT04417660 ↗
Active, not recruiting
National Cancer Institute (NCI)
Focused size, estimated: 1–150 verified statements once built

We haven't built an HCP commentary report on NCT04417660 (bintrafusp alfa in thymoma and thymic carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on NCT04417660 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
3 posts on X, typically up to 13 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Phase: Phase 2
Status: Active, not recruiting
Conditions: Thymic Epithelial Tumor; Recurrent Thymoma; Thymic Cancer
Interventions: M7824
Arms: Bintrafusp alfa (M7824) · Experimental
Enrollment: 9
Primary outcomes: Objective response rate
Sponsor: National Cancer Institute (NCI)
Start: Dec 26, 2020
Primary completion: Dec 31, 2026 (estimated)
Results posted: No
Registry record: NCT04417660 · updated Oct 16, 2026

Publications

linked from the registry

Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. PubMed 34393061